News
TRVN
0.4076
-0.34%
-0.0014
Weekly Report: what happened at TRVN last week (0415-0419)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Chromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. Kineta stock moved upwards by 16.62% and Erasca stock rose 13.73%. Nexalin Technology (NASDAQ:NXL) stock fell 18.4% during the day.
Benzinga · 04/19 12:08
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday's pre-market session. 23andMe Holding stock moved upwards by 26.61% in the pre- market session. NRX Pharmaceuticals shares declined by 22.5% during the session.
Benzinga · 04/18 12:09
12 Health Care Stocks Moving In Wednesday's After-Market Session
Trevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday's after-market session. Mustang Bio stock increased by 11.97% and SINTX Techs stock rose 10.32% in the same session. Losers TRACON Pharma and DIH Holding US stock fell by 16.6% and 14.05% respectively.
Benzinga · 04/17 20:31
Weekly Report: what happened at TRVN last week (0408-0412)?
Weekly Report · 04/15 10:15
TREVENA INC - ON APRIL 5, RECEIVED NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM NASDAQ
Reuters · 04/09 20:09
Weekly Report: what happened at TRVN last week (0401-0405)?
Weekly Report · 04/08 10:18
Trevena Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/02 12:55
HC Wainwright & Co. Maintains Buy on Trevena, Maintains $9 Price Target
Benzinga · 04/02 12:44
Buy Rating Affirmed on Trevena as Focus Shifts to Promising Drug Candidate TRV045
Analyst Douglas Tsao from H.C. Wainwright maintained a Buy rating on Trevena (TRVN – Research Report) and kept the price target at $9.00. Tsao’s confidence in the company is based on the potential of their drug candidate, TRV045. The drug candidate shows promise in the treatment of diabetic neuropathy pain and epilepsy.
TipRanks · 04/02 10:26
Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising TRV045 Development
TipRanks · 04/01 17:35
Recap: Trevena Q4 Earnings
Trevena will report its Q4 earnings on Monday, April 1, 2024. Trevena missed estimated earnings by -179.0%, missing by $1.06. The company's revenue is expected to be down $81 thousand from the same period last year. Last quarter the company missed on EPS by $0.42.
Benzinga · 04/01 13:40
Trevena Inc reports results for the quarter ended in December - Earnings Summary
Trevena Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $1.06 per share. Revenue was $-81.00 thousand; analysts expected revenue of $143.50 million. Trevena shares have lost 36.3% this year.
Reuters · 04/01 13:31
Trevena Inc: Annual report
Press release · 04/01 12:03
*Trevena 4Q Rev Negative $81,000 >TRVN
Dow Jones · 04/01 11:03
TREVENA INC - CONDUCTING A REVIEW OF STRATEGIC ALTERNATIVES FOR OLINVYK
Reuters · 04/01 11:00
Press Release: Trevena Reports Fourth Quarter -3-
Any statements in this press release about future expectations, plans and prospects for the Company are forward-looking statements. Actual results may differ from those expressed or implied by such statements. The Company's strategy, future operations, clinical development and trials of its therapeutic candidates are uncertain.
Dow Jones · 04/01 11:00
Press Release: Trevena Reports Fourth Quarter -2-
OLINVYK is an opioid agonist indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic. The risk of addiction, abuse, and misuse with opioids is high. The cumulative total daily dose should not exceed 27 mg. Advise pregnant women of the risk of neonatal withdrawal syndrome.
Dow Jones · 04/01 11:00
*Trevena 4Q Loss $16.5M >TRVN
Dow Jones · 04/01 11:00
*Trevena 4Q Loss/Shr $1.06 >TRVN
Dow Jones · 04/01 11:00
More
Webull provides a variety of real-time TRVN stock news. You can receive the latest news about Trevena Inc through multiple platforms. This information may help you make smarter investment decisions.
About TRVN
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).